Anika Beats on Revenue Growth, Raises EBITDA Outlook Despite Hyalofast FDA Rejection
ANIK has more than doubled off its 52-week low of $9.01.
Summary
Anika posted Q3 2026 revenue of $30.6 million, up 10% year over year, with Commercial Channel revenue up 17% to $14.0 million and OEM Channel up 5% to $16.6 million. Gross margin jumped to 62% from 56%, and adjusted EBITDA came in at $5.1 million versus $0.9 million a year ago. The company raised the low end of its 2026 total revenue growth range to 6%-10% from 5%-10% and lifted 2026 adjusted EBITDA margin guidance to 15%-17% from 13%-17%, though it cut Commercial Channel growth guidance to 9%-13% from 12%-18% on a slower elective surgery market. Two items carry real weight: a new 10-year Hyvisc distribution deal with Boehringer Ingelheim that brings $8 million in total payments including a $4 million upfront in Q1 2027, and an October FDA notice that the Hyalofast PMA application is not approvable on the clinical data submitted. Cash stood at $45.0 million at quarter end. The 2027 revenue outlook of flat to 5% growth is the number to focus on — it implies a sharp deceleration from 2026 and sits alongside the Hyalofast setback.
At the time of this announcement, ANIK was trading at $18.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $258.7M. The 52-week trading range was $9.01 to $22.88. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.